[go: up one dir, main page]

DE69526958D1 - Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten - Google Patents

Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten

Info

Publication number
DE69526958D1
DE69526958D1 DE69526958T DE69526958T DE69526958D1 DE 69526958 D1 DE69526958 D1 DE 69526958D1 DE 69526958 T DE69526958 T DE 69526958T DE 69526958 T DE69526958 T DE 69526958T DE 69526958 D1 DE69526958 D1 DE 69526958D1
Authority
DE
Germany
Prior art keywords
antibacterial
salts
products containing
aminothiazole derivatives
bactericidal products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526958T
Other languages
English (en)
Other versions
DE69526958T2 (de
Inventor
Terushi Hashiguchi
Toshio Yoshida
Toshio Itoyama
Yasuaki Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hisamitsu Pharmaceutical Co Inc
Original Assignee
Hisamitsu Pharmaceutical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hisamitsu Pharmaceutical Co Inc filed Critical Hisamitsu Pharmaceutical Co Inc
Application granted granted Critical
Publication of DE69526958D1 publication Critical patent/DE69526958D1/de
Publication of DE69526958T2 publication Critical patent/DE69526958T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69526958T 1994-11-29 1995-11-16 Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten Expired - Fee Related DE69526958T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP31773794 1994-11-29
JP33538894 1994-12-22
PCT/JP1995/002347 WO1996016650A1 (fr) 1994-11-29 1995-11-16 Antibacterien et bactericide comprenant un derive de 2-aminothiazole et sels de ce derive

Publications (2)

Publication Number Publication Date
DE69526958D1 true DE69526958D1 (de) 2002-07-11
DE69526958T2 DE69526958T2 (de) 2003-01-16

Family

ID=26569125

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526958T Expired - Fee Related DE69526958T2 (de) 1994-11-29 1995-11-16 Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten

Country Status (8)

Country Link
US (1) US5856347A (de)
EP (1) EP0790057B1 (de)
KR (1) KR980700077A (de)
AU (1) AU689972B2 (de)
CA (1) CA2206315A1 (de)
DE (1) DE69526958T2 (de)
TW (1) TW414708B (de)
WO (1) WO1996016650A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4508294B2 (ja) * 1995-06-22 2010-07-21 スリーエム カンパニー 安定なヒドロアルコール組成物
US6623744B2 (en) * 1995-06-22 2003-09-23 3M Innovative Properties Company Stable hydroalcoholic compositions
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6582711B1 (en) * 1997-01-09 2003-06-24 3M Innovative Properties Company Hydroalcoholic compositions thickened using polymers
DE19700795A1 (de) * 1997-01-13 1998-07-16 Bayer Ag Verwendung von Aminothiazolen zur Wund- und Hautbehandlung
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
JP2002514633A (ja) * 1998-05-12 2002-05-21 アメリカン・ホーム・プロダクツ・コーポレイション （２−アシルアミノチアゾール−４−イル）酢酸誘導体
EP1191948A2 (de) * 1999-06-11 2002-04-03 Neorx Corporation Hochdosierte radionuklide komplexe zur knochenmark-unterdrückung
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
WO2002062398A2 (en) 2001-01-08 2002-08-15 Neorx Corporation Radioactively labelled conjugates of phosphonates
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
EP1285914B1 (de) * 2001-08-13 2007-12-19 PheneX Pharmaceuticals AG Nr1h4-kern-rezeptor-bindende verbindungen
CA2451980C (en) 2001-08-13 2012-12-11 Janssen Pharmaceutica N.V. 2-amino-4,5-trisubstituted thiazolyl derivatives and their use against autoimmune disorders
WO2003015777A1 (en) * 2001-08-13 2003-02-27 Lion Bioscience Ag Nr1h4 nuclear receptor binding compounds
CA2461363A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
PL370111A1 (en) * 2001-11-22 2005-05-16 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7094792B2 (en) * 2001-11-22 2006-08-22 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7074788B2 (en) 2001-11-22 2006-07-11 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2007205749B2 (en) * 2001-11-22 2009-04-23 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7045116B2 (en) 2001-12-13 2006-05-16 Dow Global Technologies Inc. Treatment of osteomyelitis with radiopharmaceuticals
MY156407A (en) * 2002-02-28 2016-02-26 Novartis Ag 5-phenylthiazole derivatives and use as p13 kinase inhibitors
CN100357283C (zh) * 2002-04-02 2007-12-26 中国科学院上海药物研究所 一类甲硫氨酰氨肽酶抑制剂
JP2007506684A (ja) 2003-09-29 2007-03-22 エセナ ヘルスケア インコーポレーテッド アルコール含有量の高いゲル様組成物及びフォーミング組成物
BRPI0418082B8 (pt) * 2003-12-26 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de tiazol úteis como antagonistas de receptor de adenosina a2a
US20050239853A1 (en) * 2004-02-04 2005-10-27 Tjeerd Barf New compounds
BRPI0515012A (pt) 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
DE102004062775A1 (de) 2004-12-21 2006-06-29 Stockhausen Gmbh Alkoholischer Pumpschaum
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN101170904A (zh) * 2005-03-07 2008-04-30 戴博全球保健有限公司 含有有机硅基表面活性剂的高醇含量发泡组合物
MX2007013955A (es) 2005-05-09 2008-02-05 Achillion Pharmaceuticals Inc Compuestos de tiazol y metodos de uso.
US7651990B2 (en) * 2005-06-13 2010-01-26 3M Innovative Properties Company Foamable alcohol compositions comprising alcohol and a silicone surfactant, systems and methods of use
EP1894930A4 (de) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd Thiazolderivat
KR20080030031A (ko) 2005-07-29 2008-04-03 가부시키가이샤 시세이도 모발 생기·탄력 개선제 및 모발용 화장료
US20070148101A1 (en) * 2005-12-28 2007-06-28 Marcia Snyder Foamable alcoholic composition
EP1981884B1 (de) * 2006-01-18 2012-06-13 Amgen, Inc Thiazolverbindungen als proteinkinase b (pkb)-inhibitoren
EP2460800A1 (de) * 2006-03-08 2012-06-06 Achillion Pharmaceuticals, Inc. Subsituierte Aminothiazol-derivate mit Anti-HCV-Aktivität
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
EP2054056A4 (de) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa Kleinmolekulare hemmer von kynurenin-3-monooxygenase
US7994338B2 (en) * 2006-08-16 2011-08-09 The J. David Gladstone Institutes Small molecule inhibitors of kynurenine-3-monooxygenase
CN101801964A (zh) 2007-05-22 2010-08-11 艾其林医药公司 杂芳基取代的噻唑及其作为抗病毒剂的用途
JP5411850B2 (ja) * 2007-06-21 2014-02-12 アムジエン・インコーポレーテツド 置換２−アミノ−チアゾロンを作製するための方法
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
HRP20120948T1 (hr) 2007-10-09 2012-12-31 Merck Patent Gmbh Derivati piridina koji su korisni kao aktivatori glukokinaze
US8106209B2 (en) 2008-06-06 2012-01-31 Achillion Pharmaceuticals, Inc. Substituted aminothiazole prodrugs of compounds with anti-HCV activity
AU2010226857B2 (en) * 2009-03-20 2016-07-14 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
DE102010004950A1 (de) * 2010-01-18 2011-07-21 Remis Gesellschaft für Entwicklung und Vertrieb von technischen Elementen mbH, 50829 Kühlregal mit Türvorrichtung
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
DE102011083271A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
JP6038184B2 (ja) 2012-02-01 2016-12-07 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ リボヌクレオチドレダクターゼ阻害剤および使用方法
JP7193071B2 (ja) * 2017-02-08 2022-12-20 国立大学法人東海国立大学機構 蛍光発光材料および紫外線吸収剤
WO2020051424A1 (en) 2018-09-07 2020-03-12 Pic Therapeutics Eif4e inhibitors and uses thereof
PH12022551139A1 (en) * 2019-11-12 2023-07-17 Genzyme Corp 5-membered heteroarylaminosulfonamides for treating conditions mediated by deficient cftr activity
CN111166743B (zh) * 2020-01-02 2022-03-22 中国医学科学院医药生物技术研究所 一类含噻唑结构化合物的抗感染用途
CA3170411A1 (en) 2020-03-03 2021-09-10 Christopher L. Vandeusen Eif4e inhibitors and uses thereof
CN113968852B (zh) * 2020-07-23 2023-08-15 同济大学 一种噻唑酰肼类衍生物及其制备方法和应用
US12234231B2 (en) 2021-08-25 2025-02-25 PIC Therapeutics, Inc. EIF4E inhibitors and uses thereof
JP2024532276A (ja) 2021-08-25 2024-09-05 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04173782A (ja) * 1990-11-08 1992-06-22 Taisho Pharmaceut Co Ltd ２―スルホンアミド―４，５―ジフェニルチアゾール誘導体
DE69132293D1 (de) * 1991-03-07 2000-08-10 Hisamitsu Pharmaceutical Co Diphenylthiazolderivate mit antiinflammatorischer aktivität
JPH0570446A (ja) * 1991-09-13 1993-03-23 Taisho Pharmaceut Co Ltd Ｎ−チアゾリルスルホンアミド誘導体
JPH0673032A (ja) * 1992-07-07 1994-03-15 Nippon Soda Co Ltd チアゾール誘導体及びその製法
JPH07149746A (ja) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−置換アミノチアゾール誘導体
JPH07149745A (ja) * 1993-11-30 1995-06-13 Hisamitsu Pharmaceut Co Inc 新規な２−アミノチアゾール誘導体

Also Published As

Publication number Publication date
TW414708B (en) 2000-12-11
DE69526958T2 (de) 2003-01-16
EP0790057A4 (de) 1998-10-21
AU689972B2 (en) 1998-04-09
US5856347A (en) 1999-01-05
EP0790057B1 (de) 2002-06-05
CA2206315A1 (en) 1996-06-06
WO1996016650A1 (fr) 1996-06-06
EP0790057A1 (de) 1997-08-20
KR980700077A (ko) 1998-03-30
AU3880995A (en) 1996-06-19

Similar Documents

Publication Publication Date Title
DE69526958D1 (de) Antibakterielle oder bakterizide mittel, die 2-aminothiazolderivate und deren salze enthalten
DE69011439D1 (de) Neue kosmetische Präparate die Chitosan und Glucosamin enthalten.
DE69524813D1 (de) Verdickte kosmetische Mittel
DE69515007D1 (de) Stabile kosmetische, dermatologische oder pharmazeutische Zusammensetzung, die Seleniumdisulfid und mindestens ein Zinksalz enthält
DE69637240D1 (de) Antibakterielles/bakterizides/antiseptisches mittel, dermatologische zubereitung und tensidzusammensetzung
DE69619389D1 (de) Absorbierender artikel mit flügel, die eine deformierteknickzone und dehnbare zonen enthalten
AT399658B (de) Anlage zum sterilisieren, pasteurisieren und/oder desinfizieren pump- oder rieselfähiger medien
DE10199027I2 (de) Fluorcytidinderivate deren Herstellung und Arzneimittel die diese Derivate enthalten
FI972313A0 (fi) Uusia 2,3-diketopiperatsiinijohdannaisia ja niiden suoloja
DE3682964D1 (de) Praeparate, die poly(aethylenisch ungesaettigte) carbamoylisocyanurate enthalten, und deren verwendung bei der zahnbehandlung.
DE69907698D1 (de) Azetidinderivate, deren herstellung und sie enthaltende arzneimittel
DE69227581D1 (de) Zahnputzmittel, die antibakterielle quartäre ammoniumverbindungen und ausgewählte calcium-schleifmittel enthalten
PH22801A (en) 1,4-dihydro-4-oxonaphthyridine derivatives and salts thereof and antibacterial agents comprising the same
DE69531305D1 (de) Pyridoncarboxylat- derivate oder salze davon und antibakterielle zusammensetzungen die diese als aktiven bestandteil enthalten
DE69425153D1 (de) Pseudodipeptid-produkte, die eine imidazol-gruppe enthalten und ihre anwendungen
ATA95989A (de) Pyridoncarbonsäurederivate und salze hievon, verfahren zur herstellung derselben und antibakterielle mittel, welche diese enthalten
DE69006069D1 (de) Mittel für die orale Hygiene.
DE69513803D1 (de) Alumoxanen und katalysatore die alumoxanen enthalten
DE69203512D1 (de) Kosmetisches Mittel gegen die Hautalterung, eine Kombination aus mindestens einem Retinoid und mindestens einen Dialkyl- oder Trialkylxanthin enthaltend.
DE69531722D1 (de) Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
ATE90510T1 (de) Antimikrobische zusammensetzung und deren verwendung.
DE69624343D1 (de) Pharmazeutische zusammensetzungen, welche ein benzydamin oder deren salz und einen antimikrobiellen wirkstoff enthalten
DE69323134D1 (de) Zusammensetzungen, die Produkte enthalten, die das Zusammenbacken verhindern und Behandlungen mit diesen Zusammensetzungen
DE69300521D1 (de) Hautpflegemittel.
DE3889198D1 (de) Cephalosporinverbindungen und antibakterielle Mittel.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee